NCT03489044.

Study name	An Investigation of Levetiracetam in Alzheimer's Disease
Methods	Double‐blind, randomized, cross‐over assignment
Participants	Meets the National Institute of Aging‐Alzheimer's Association criteria for probable AD
Interventions	Levetiracetam and placebo
Outcomes	Hippocampal function, mood, quality of life and adverse events
Starting date	April 2018
Contact information	Arjune Sen, PhD, FRCPE. Nuffield Department of Clinical Neurosciences
Notes	Estimated Study Completion Date: December 2019

AD: Alzheimer's disease; CDR: Clinical Dementia Rating; MMSE: Mini Mental Status Exam